香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Jinhai Medical Technology Limited 今海醫療科技股份有限公司 （於開曼群島註冊成立的成員有限責任公司） （股份代號：2225） 有關 二零二四年報之補充公告 茲提述今海醫療科技股份有限公司（「本公司」，連同其附屬公司「本集團」）二零 二四年之年報（「年報」）、本公司日期為二零二四年四月九日有關物業收購及股份 收購之公告（「主要交易公告」）及本公司日期為二零二四年六月二十四日有關物 業收購及股份收購之通函（「主要交易通函」）。 茲亦提述本公司日期為二零二三年十二月八日之通函、本公司於二零二三年十二 月八日發佈之購股權計劃（「購股權計劃」）及本公司日期為二零二三年十二月 二十九日有關採納購股權計劃之投票表決結果公告、本公司日期為二零二四年一 月九日之公告、本公司日期為二零二四年一月二十九日之通函及本公司日期為二 零二四年二月十九日有關根據購股權計劃授出購股權之投票表決結果公告 ...

点击蓝字，关注我们 今日上午港股 1.云顶新耀 (01952) 再涨超 3% ， 近日集中展示 AI+mRNA 平台 可逆 BTK 治疗膜性肾病更新优异数据。 2.航空股早盘回落， 中国国航 (00753) 跌 3.21%，东方航空 (00670) 跌 2.88%，南方航空 (01055) 跌 1.79%，国泰航空 (00293) 跌 1.1%。 3.容大科技 (09881) 跌超 13%， 消息面上，7 月 3 日晚，容大科技发布公告称，已接获福建省厦门市中 级人民法院发出的民事起诉。 4.九兴控股 (01836) 涨超 3% ， 机构称关税等外部扰动下订单仍饱满 预计公司品牌下单积极。 5.中烟香港 (06055) 涨超 4% ， 机构建议关注中烟香港全球化及中烟资产注入进程。 6.大洋集团 (01991) 一度暴涨近 75% ， 拟溢价约 90% 配股净筹约 3439 万港元。 7.方舟健客 (06086) 盘中拉升逾 10% ，消息面上，近日，网经社发布榜单数据显示，方舟健客网上药店 APP 登顶 6 月 AppStore 中国免费榜 (医疗)。 8.黄金股集体走低， 赤峰黄金 (06693) 跌 4 ...

Corporate Strategy and Development - The company has relocated its headquarters from Singapore to China to better align with its medical business development and future prospects[10]. - The company plans to diversify its business and expand into the Asia-Pacific region, including providing value-added services such as skills training[14]. - The company anticipates steady growth in medical device demand driven by an aging population and rising living standards in China[12]. - The company will broaden its product line and enhance R&D capabilities to improve competitiveness by 2025[12]. - The company aims to strengthen its position in the medical industry through resource integration and continuous product development[12]. - The group plans to enhance its development capabilities, expand its distribution network, and develop new products to strengthen its competitive position in the medical industry[20]. - The board is considering diversifying its business and expanding existing operations into the Asia-Pacific region, particularly China[24]. - The company is actively seeking more trade partners and market expansion opportunities amid economic challenges in 2025[14]. Financial Performance - The group's revenue increased from SGD 45.6 million in FY2023 to SGD 50.2 million in FY2024, representing a growth of 10%[25]. - Revenue from minimally invasive surgical solutions and related medical products rose from SGD 20.4 million in FY2023 to SGD 25.9 million in FY2024, an increase of SGD 5.5 million[26]. - The gross profit decreased from SGD 12.0 million in FY2023 to SGD 11.5 million in FY2024, with a gross margin decline from 26.4% to 22.8%[28]. - The group recorded a loss of SGD 18.3 million in FY2024, compared to a loss of SGD 4.1 million in FY2023, primarily due to share-based payments of SGD 13.2 million and expenses related to expanding its minimally invasive surgical solutions business in China[34]. - The group recorded an unrealized foreign exchange gain of SGD 0.3 million in FY2024 due to the appreciation of SGD against HKD and RMB[47]. - The financing costs increased by SGD 0.6 million in FY2024 due to new financing obtained during the year[32]. - The group has a total of 488 employees as of December 31, 2024, down from 694 employees in the previous year[58]. Corporate Governance - The company has adopted the corporate governance code as per the listing rules, demonstrating commitment to good governance practices[82]. - The board consists of eight members, including four executive directors and three independent non-executive directors, ensuring a balanced composition for independent judgment[88]. - The company has three independent non-executive directors, meeting the requirement that they constitute at least one-third of the board[89]. - All independent non-executive directors have confirmed their independence in accordance with the listing rules, ensuring compliance with governance standards[89]. - Continuous professional development programs have been provided to directors, enhancing their understanding of governance and responsibilities[92]. - The board is responsible for overseeing the management of the group's business affairs and overall performance, ensuring necessary financial and human resources are in place[84]. - The company has established various committees to delegate responsibilities, enhancing operational efficiency and accountability[84]. Risk Management and Compliance - The company has established a risk management and internal control system to ensure effective monitoring and evaluation of risks, with regular reports on risk assessment and management effectiveness[135]. - The company is committed to enhancing its risk management and internal control systems to ensure ongoing effectiveness[138]. - There are no significant deviations in risk management and internal controls across subsidiaries, and no major litigation risks have been reported[138]. - The company will continue to improve its compliance with financial reporting and legal regulations across all subsidiaries[138]. - The company has implemented a fair disclosure policy to ensure timely and equal access to information for shareholders and investors[140]. Shareholder Relations and Dividends - The board will keep shareholders informed of significant events as they occur[15]. - The company expresses gratitude to shareholders, customers, business partners, management, and employees for their ongoing support[16]. - The board does not recommend any dividend payment for FY2024, consistent with FY2023[35]. - The net proceeds from the listing amounted to HKD 82.6 million (approximately SGD 14.1 million), with planned allocations including SGD 20.5 million for registered capital injection into Jin Hai Medical[39]. - The net proceeds from the placement on October 18, 2023, were HKD 99 million, with a subscription price of HKD 1.60 per share, reflecting a discount of 19.6% to the market price at the time[43]. Leadership and Management - The company has established a strong leadership team with diverse backgrounds in banking, real estate, and technology sectors[71]. - The company is focused on strategic management and development in real estate, including property management and project oversight[68]. - The leadership team is expected to drive future growth through strategic decision-making and market expansion initiatives[75]. - The chairman and CEO roles are held by different individuals, ensuring a separation of responsibilities[106]. Environmental and Social Responsibility - The group has established an environmental management system to address its carbon footprint, particularly focusing on indirect greenhouse gas emissions from electricity usage[168]. - There were no instances of non-compliance with environmental laws and regulations during the fiscal year[168]. - The group made a total donation of SGD 108,000 during the year, consistent with the previous fiscal year[165]. Stock Options and Shareholder Equity - The company has adopted a share option scheme approved by shareholders on December 29, 2023, allowing eligible participants to acquire ownership interests in the company[188]. - A total of 128,603,750 stock options were granted on January 9, 2024, with an exercise price of HKD 2.54 per share[194]. - The stock options will vest in three tranches: 20% on April 30, 2025, 30% on April 30, 2026, and 50% on April 30, 2027[196]. - The total number of stock options granted to the executive director and CEO, Wang Zhenfei, is 25,850,000[199].

Financial Performance - Total revenue for the fiscal year ending December 31, 2024, was SGD 50,241,000, representing an increase of 10.4% from SGD 45,644,000 in 2023[4] - Gross profit decreased to SGD 11,477,000, down 4.6% from SGD 12,029,000 in the previous year[4] - The company reported a net loss of SGD 18,255,000 for the fiscal year, compared to a net loss of SGD 4,112,000 in 2023, indicating a significant increase in losses[4] - Basic and diluted loss per share was SGD 0.35, compared to SGD 0.06 in the previous year, indicating a worsening financial position[5] - The company reported a pre-tax loss of SGD 18,227,000 for 2024, compared to a loss of SGD 3,217,000 in 2023[12] - The group recorded a net loss of SGD 18.3 million in FY2024, compared to a loss of SGD 4.1 million in FY2023, primarily due to share-based payments and expenses related to expanding minimally invasive surgical solutions in China[38] Revenue Breakdown - Customer contract revenue for 2024 was SGD 41,822,000, up 12.5% from SGD 37,029,000 in 2023[11] - Revenue from dormitory services generated rental income of SGD 8,419,000, slightly down from SGD 8,615,000 in 2023[11] - Revenue from minimally invasive surgical solutions and related services rose from SGD 20.4 million in FY2023 to SGD 25.9 million in FY2024, a significant increase of 26.9%[30] - The group experienced a slight decline in revenue from labor dispatch and related services, from SGD 15.8 million in FY2023 to SGD 15.1 million in FY2024, attributed to a sluggish market in Singapore[31] Expenses and Costs - Administrative expenses surged to SGD 31,942,000, up 100% from SGD 15,941,000 in the prior year[4] - The company incurred total financing costs of SGD 773,000 in 2024, significantly higher than SGD 221,000 in 2023[16] - Research and development expenses increased to SGD 850,000 in 2024 from SGD 633,000 in 2023[17] - The company reported a significant increase in employee costs, totaling SGD 30,545,000 in 2024, compared to SGD 18,324,000 in 2023[17] - Administrative expenses increased by SGD 16.0 million, mainly due to share-based payments of SGD 13.2 million and hiring of industry professionals[35] Assets and Liabilities - Total assets decreased to SGD 58,867,000 from SGD 62,220,000, reflecting a decline of 5.5%[6] - Cash and cash equivalents dropped significantly to SGD 10,446,000 from SGD 20,196,000, a decrease of 48.2%[6] - The company’s total liabilities increased to SGD 26,088,000, up from SGD 24,730,000, marking a rise of 5.5%[7] - The company’s non-current assets rose to SGD 28,703,000, up from SGD 19,538,000, an increase of 46.7%[6] - Trade receivables decreased to SGD 4,856,000 from SGD 5,531,000, a decline of 12.2%[6] - Trade payables decreased to SGD 5,129,000 in 2024 from SGD 5,462,000 in 2023, with accrued operating expenses increasing to SGD 2,543,000 from SGD 2,371,000[23] Shareholder Information - The company did not declare or pay any dividends for the years ended December 31, 2024, and 2023[18] - The company completed a share split on December 12, 2024, adjusting the number of shares from 1,292,500,000 to 5,170,000,000[24] - A total of 128,603,750 share options were granted on January 9, 2024, with an exercise price of HKD 2.54 per share[74][75] - As of December 31, 2024, there are 509,245,000 unexercised stock options, adjusted for the share split effective on December 12, 2024[78] Market and Strategic Outlook - The company plans to expand its distribution network and develop new products to enhance competitiveness in the medical industry[26] - The minimally invasive surgical device market in China is projected to grow from USD 1.71 billion in 2025 to USD 2.68 billion by 2030, with a compound annual growth rate of 9.45% from 2024 to 2029[26] - The company is considering diversifying its business and expanding into the Asia-Pacific region, particularly China, to improve business prospects[28] - The company aims to leverage advantages in China, Hong Kong, and Singapore to explore new investment opportunities and enhance long-term economic benefits for shareholders[28] Risk Management - The group faces cash flow interest rate risk due to floating interest rates on bank balances and fixed-rate financing leases, with no current interest rate hedging policy in place[61] - The group is exposed to foreign currency risk due to bank balances and financial assets denominated in USD and RMB, which are not the functional currencies of the group entities[62] - Credit risk has been significantly reduced through established policies for credit limits and monitoring overdue debts, with management regularly reviewing the recoverability of trade debts[64] - The group maintains sufficient levels of cash and cash equivalents to manage liquidity risk and mitigate cash flow volatility[65] Corporate Governance - The audit committee reviewed the annual performance and confirmed that the consolidated financial statements were prepared in accordance with applicable accounting standards[87] - The company maintained sufficient public float throughout the year as per listing rules[89] - The board has adopted the corporate governance code and complied with all applicable provisions during the year[86] - The company expresses gratitude to all customers, management, employees, business partners, and shareholders for their continued support[91]

今遍医疗 ＩＮＨＡＩＭＥＤ J Jinhai Medical Technology Limited 今 海 醫 療 科 技 股 份 有 限 公 司 (於周曼群島註冊成立的成員有限责任公司) (股份代號：2225) ULS SBD 12 DBP 80 STATUS: LETE A a FUNC ATAT : STABLE 202 中 期 報 告 目錄 頁次 公司資料 02 簡明綜合損益及其他全面收益表 04 簡明綜合財務狀況表 05 簡明綜合權益變動表 07 簡明綜合現金流量表 08 簡明綜合財務報表附註 09 管理層討論及分析 22 企業管治及其他資料 32 BTE FUNC ATAT 公司資料 余明陽先生（於二零二四年八月五日辭任） | --- | --- | |---------------------------------------------------|-------------------------------------------------------------------------------| | 董事會 | 公司秘書 | | 執行董事 | 黃文耀先生（於二零二四年一月一日辭任 ...

Financial Performance - For the six months ended June 30, 2024, the company reported revenue of SGD 25,937 thousand, a significant increase from SGD 11,983 thousand in the same period of 2023, representing a growth of approximately 116.5%[3] - The gross profit for the first half of 2024 was SGD 7,422 thousand, compared to SGD 5,049 thousand in the first half of 2023, indicating a growth of about 46.8%[3] - The company incurred a loss before tax of SGD 5,941 thousand for the period, compared to a profit of SGD 592 thousand in the same period last year, reflecting a decline in profitability[3] - The company reported a net loss of SGD 6,043,000 for the six months ended June 30, 2024, compared to a profit of SGD 940,000 in the same period of 2023[23] - The company reported a basic and diluted loss per share of SGD (0.47) for the first half of 2024, compared to earnings of SGD 0.08 per share in the same period of 2023[5] - Gross profit rose from SGD 5.0 million in the first half of 2023 to SGD 7.4 million in the first half of 2024, although the gross margin decreased from 42.1% to 28.6%[35] - Administrative expenses increased significantly from SGD 4.8 million to SGD 13.7 million, primarily due to post-COVID-19 recovery costs and share-based payments[37] - The company recorded a loss attributable to shareholders of SGD 6.0 million in the first half of 2024, compared to a profit of SGD 0.9 million in the same period of 2023[38] Revenue Breakdown - Revenue for the six months ended June 30, 2024, was SGD 25,937,000, a significant increase from SGD 11,983,000 in the same period of 2023, representing a growth of approximately 116%[14] - Revenue from Singapore reached SGD 13,505,000, up from SGD 11,587,000, indicating a growth of about 16.5% year-over-year[14] - Revenue from mainland China surged to SGD 12,432,000, compared to only SGD 396,000 in the previous year, reflecting a remarkable increase of over 3,000%[14] - Revenue from minimally invasive surgical solutions and related medical products surged from SGD 0.4 million to SGD 12.3 million, a staggering increase of 3,006.6%[32] - The revenue from dormitory services increased from SGD 3.6 million to SGD 5.6 million, driven by high market demand and increased pricing in the first half of 2024[34] Assets and Liabilities - The total assets of the company as of June 30, 2024, amounted to SGD 64,851 thousand, an increase from SGD 62,220 thousand as of December 31, 2023[6] - The company's total liabilities increased to SGD 27,154 thousand as of June 30, 2024, compared to SGD 24,730 thousand at the end of 2023, indicating a rise of approximately 9.8%[8] - The net cash balance decreased to SGD 13,173 thousand from SGD 20,196 thousand at the end of 2023, representing a decline of about 34.7%[6] - The group’s total borrowings and lease liabilities as of June 30, 2024, were SGD 11.3 million, an increase from SGD 10.1 million as of December 31, 2023, primarily due to new borrowings[50] - The debt-to-equity ratio as of June 30, 2024, was 30.0%, up from 26.9% as of December 31, 2023[50] Investments and Acquisitions - The company acquired investment properties worth SGD 10,515,000 during the six months ended June 30, 2024, with no acquisitions reported in the same period of 2023[24] - The company completed the acquisition of Neuhaus Engineering Pte. Ltd. on November 30, 2023, making it a wholly-owned subsidiary[54] - The group has reallocated SGD 10.0 million to acquire listed securities in the public market due to delays in acquiring foreign worker dormitories[43] Cash Flow and Financing - The net proceeds from the listing amounted to HKD 82.6 million (equivalent to SGD 14.1 million) after deducting underwriting fees and listing expenses[41] - The group has a remaining undrawn bank financing of SGD 3.0 million as of June 30, 2024, compared to SGD 2.5 million as of December 31, 2023[50] - The group maintains a prudent treasury policy to ensure a robust financial position and closely monitors its liquidity[40] Employee and Shareholder Information - Employee costs for the first half of 2024 were SGD 13.6 million, up from SGD 6.3 million in the first half of 2023[57] - The average number of ordinary shares outstanding increased to 1,292,500 for the six months ended June 30, 2024, compared to 1,230,000 in the same period of 2023[23] - The company granted a total of 128,603,750 share options under the share option plan on January 9, 2024, allowing holders to subscribe for the same number of shares[64] - The exercise price for the share options is set at HKD 2.54 per share, which is the highest of the closing price on the grant date or the average closing price over the previous five trading days[65] - The vesting schedule for the share options includes three tranches: 20% vesting on April 30, 2025, 30% on April 30, 2026, and 50% on April 30, 2027[66] Corporate Governance and Compliance - The company has adopted all applicable principles of the corporate governance code as per the listing rules, with no significant non-compliance reported[71] - The audit committee has reviewed the unaudited interim results and confirmed that the financial information complies with applicable accounting standards and listing rules[72] - The interim results announcement has been published on the Hong Kong Stock Exchange website and the company's website, ensuring transparency for shareholders[73] - All directors confirmed compliance with the trading code for securities transactions during the reporting period[69] Future Plans and Market Outlook - The company plans to continue expanding its service offerings in labor dispatch and IT services, which have shown growth in revenue[12] - The company plans to enhance its competitive position in the medical industry by strengthening development capabilities, expanding distribution networks, and developing new products[30] - The minimally invasive surgical instruments market in China is projected to grow from USD 1.56 billion in 2024 to USD 2.45 billion by 2029, with a compound annual growth rate of 9.45%[30] - The company aims to explore various fundraising methods in capital markets in Hong Kong and other locations to support business development[30] Risk Management - The company is facing economic uncertainty due to inflation and rising interest rates, prompting a more aggressive approach to managing internally generated funds[56] - The company has established policies to mitigate credit risk, including credit limits and approval processes[60] - The company has no interest rate hedging policies currently in place but monitors interest rate risks[58] - The company has no significant contingent liabilities as of June 30, 2024[53] - The company has no significant off-balance-sheet transactions as of June 30, 2024[57] Workforce Changes - The company has reduced its workforce from 694 employees as of December 31, 2023, to 508 employees as of June 30, 2024[57]

Financial Performance - The company recorded revenue of SGD 45.6 million for the fiscal year 2023, an increase of 105% compared to SGD 22.3 million in fiscal year 2022[22]. - Revenue from minimally invasive surgical solutions and related medical products surged to SGD 20.4 million in fiscal year 2023, up from SGD 0.7 million in fiscal year 2022, marking an increase of SGD 19.7 million[24]. - The gross profit increased from SGD 10.1 million in fiscal year 2022 to SGD 12.0 million in fiscal year 2023, although the gross margin decreased from 45.4% to 26.4% due to lower profit margins in the minimally invasive surgical solutions business[25]. - The company reported a loss of SGD 4.1 million for fiscal year 2023, compared to a profit of SGD 0.1 million in fiscal year 2022, mainly due to expenses incurred in expanding the minimally invasive surgical solutions business in China[29]. - The company will not recommend any dividend payment for fiscal year 2023, consistent with the previous fiscal year[29]. Capital Management - The company has recognized the need for stricter cost management measures to conserve cash amid rising inflation and interest rates, marking 2023 as a challenging economic year[15]. - The company has adopted a prudent financial management policy to maintain a healthy financial position and closely monitors its cash flow situation[31]. - The company has cash and cash equivalents of SGD 20.2 million as of December 31, 2023, with 26.1% in SGD, 52.3% in RMB, 2.5% in USD, and 19.1% in HKD[41]. - The group has unutilized bank financing of SGD 2.5 million as of December 31, 2023, compared to SGD 0.5 million as of December 31, 2022[40]. - The company has maintained good relationships with customers and suppliers, implementing a team to address complaints and improve service quality[125]. Business Expansion and Strategy - The company successfully completed the issuance of 62,500,000 new shares at a subscription price of HKD 1.60 per share, raising a total of HKD 100 million, with approximately HKD 69 million allocated for expanding its business in the Chinese medical industry[14]. - The company plans to broaden its product line and enhance R&D capabilities in 2024 to strengthen competitiveness in the growing medical device market driven by an aging population and rising living standards in China[15]. - The company aims to continuously develop new products and expand its distribution network to consolidate its position in the medical industry[15]. - The company aims to diversify its business and expand into the Asia-Pacific region, including providing value-added services such as skills training for labor[21]. - The company plans to use net proceeds of SGD 69 million from the issuance of 62,500,000 new shares to expand its business in the Chinese medical industry[22]. Corporate Governance - The company emphasizes good corporate governance to enhance shareholder value and accountability within its management structure[64]. - The board consists of eight members, including executive directors and independent non-executive directors, ensuring a balanced composition for independent judgment[69]. - The company has established various committees to delegate responsibilities and ensure effective governance practices[67]. - The company has appointed independent non-executive directors to enhance governance and oversight functions[61]. - The board is responsible for overseeing the management of the group's business affairs and overall performance, including major financial and operational decisions[67]. Risk Management - The company has implemented guidelines for risk management and internal control, with financial personnel assigned to ensure proper functioning[103]. - The company emphasizes that risk management systems are designed to manage rather than eliminate risks associated with achieving business objectives[103]. - The company faces cash flow interest rate risk due to floating interest rates on bank balances and has no current interest rate hedging policy[48]. - The company manages foreign currency risk through close monitoring of exchange rate fluctuations, as it holds bank balances and financial assets denominated in USD and HKD[49]. - The company has identified climate-related risks and opportunities that could significantly impact its assets and services[198]. Environmental, Social, and Governance (ESG) - The company has established an environmental management system to address its carbon footprint and water conservation efforts[122]. - The company is committed to sustainable development, focusing on creating long-term value for stakeholders[122]. - The company reported a reduction in nitrogen oxides (NOx) emissions from 64.74 kg in 2022 to 62.54 kg in 2023[180]. - The total greenhouse gas emissions for the group in 2023 were 637.76 tons of CO2 equivalent, a slight decrease from 639.77 tons in 2022[185]. - The board is committed to supporting Singapore's national climate goal of achieving net-zero emissions by 2050[170]. Shareholder Communication - The board will communicate with shareholders promptly regarding significant events[15]. - The company ensures effective communication with shareholders and investors through various channels, including financial reports and annual general meetings[111]. - The company has implemented a fair disclosure policy to ensure timely and non-exclusive information dissemination[105]. - The board held four regular meetings during the year, including the approval of the audited consolidated financial statements for the year ended December 31, 2022[76]. - The company held two extraordinary general meetings on December 20 and 29, 2023, to approve changes to the company name and adopt a share option scheme[78].

Financial Performance - The company's revenue for the fiscal year ending December 31, 2023, was SGD 45,644,000, a significant increase of 105.5% compared to SGD 22,280,000 in 2022[2] - Gross profit for the year was SGD 12,029,000, up from SGD 10,116,000 in the previous year, reflecting a growth of 18.9%[2] - The company reported a net loss of SGD 4,112,000 for the year, compared to a profit of SGD 116,000 in 2022, indicating a substantial decline in profitability[2] - The company reported a net profit of SGD 1,045 thousand for 2023, recovering from a loss of SGD 4,112 thousand in 2022[12] - The total tax expense for 2023 was SGD 895 thousand, an increase from SGD 668 thousand in 2022, indicating a growth of 33.9%[18] Assets and Liabilities - Total assets increased to SGD 62,220,000 in 2023 from SGD 40,271,000 in 2022, representing a growth of 54.5%[4] - Current assets also increased to SGD 42,682,000 from SGD 33,302,000, reflecting a growth of 28.2%[4] - Non-current assets grew significantly, with property, plant, and equipment valued at SGD 2,085,000 compared to SGD 4,258,000 in the previous year[4] - Trade receivables increased to SGD 7.2 million in fiscal year 2023 from SGD 3.2 million in fiscal year 2022, with a provision for impairment of SGD 1.7 million[21] - As of December 31, 2023, the group's total borrowings and lease liabilities amounted to SGD 10.1 million, up from SGD 4.4 million a year earlier, primarily due to borrowing for the acquisition of a subsidiary[46] - The debt-to-equity ratio increased to 26.9% as of December 31, 2023, compared to 18.1% a year earlier, reflecting the increase in borrowings[46] Revenue Breakdown - Revenue from Singapore increased to SGD 25,213 thousand in 2023, up from SGD 21,624 thousand in 2022, reflecting a growth of 16.5%[10] - Revenue from China surged to SGD 20,431 thousand in 2023, compared to SGD 656 thousand in 2022, indicating a remarkable growth of 3,113.5%[10] - Service revenue, including labor dispatch and related services, rose to SGD 15,750 thousand in 2023 from SGD 15,018 thousand in 2022, an increase of 4.9%[10] - Revenue from minimally invasive surgical solutions and related medical products surged to SGD 20.4 million in fiscal year 2023, up from SGD 656,000 in fiscal year 2022, representing an increase of SGD 19.8 million[30] - Dormitory service revenue increased from SGD 5.8 million in FY2022 to SGD 8.6 million in FY2023, primarily due to previous city lockdowns and regulatory changes affecting worker dormitory capacity[31] Expenses and Costs - The company incurred financing costs of SGD 221,000, which is an increase from SGD 85,000 in the previous year[2] - Administrative expenses increased by SGD 5.7 million, primarily due to promotional and marketing expenses for the new minimally invasive surgical solutions business[34] - The group recorded a loss of SGD 4.1 million in FY2023, compared to a profit of SGD 0.1 million in FY2022, mainly due to expenses related to the expansion of minimally invasive surgical solutions in China[36] - The total employee costs for FY2023 were SGD 18.3 million, up from SGD 12.3 million in FY2022[53] Share Issuance and Capital Allocation - The company issued 62.5 million new ordinary shares at a subscription price of HKD 1.60 per share, raising a total cash amount of HKD 100 million (approximately SGD 17.47 million)[27] - The company plans to allocate SGD 69 million of the net proceeds from the share issuance to expand its business in the Chinese medical industry[28] - The group plans to allocate SGD 69.0 million for expanding its medical services and SGD 15.0 million for general operational funds by December 2024[48] Governance and Compliance - The company has adopted new and revised International Financial Reporting Standards, which did not result in significant changes to its accounting policies or financial statements[8] - The audit committee has reviewed the audited annual performance and confirmed that the consolidated financial statements are prepared in accordance with applicable accounting standards and regulations[62] - The financial figures for the year ending December 31, 2023, have been verified by the auditors, ensuring consistency with the audited financial statements[63] - The company has adhered to all applicable provisions of the corporate governance code throughout the year[61] - The annual report contains all information required by the listing rules and will be made available to shareholders in a timely manner[64] Employee and Operational Insights - The group employed 694 employees as of December 31, 2023, an increase from 520 employees in the previous year[53] - The group recorded a net capital expenditure of SGD 4.7 million in FY2023, compared to SGD 3.3 million in FY2022, primarily for the purchase of properties, plants, and equipment[51] Market Outlook - The company anticipates challenges in the Singapore construction industry in 2024, with expected economic growth slowing to between 1.0% and 3.0%[28] - The company aims to enhance its competitiveness by broadening its product line and improving R&D capabilities in response to increasing demand for medical devices in China[28]

智通财经APP讯，今海国际(02225)发布公告，于2023年12月20日举行的股东特别大会上通过特别决议案 后，开曼群岛公司注册处处长于2023年12月28日发出更改名称的公司注册证书，证明公司英文名称 由"Jinhai International Group Holdings Limited"更改为"Jinhai Medical Technology Limited"，及将公司双重 外文名称由"今海国际集团控股有限公司"更改为"今海医疗科技股份有限公司"。 公司证券于联交所买卖的英文及中文股份简称将由"JINHAI INTL"及"今海国际"分别更改为"JINHAI MED TECH"及"今海医疗科技"，自2024年2月16日上午9时正起生效。公司的股份代号将维持不变，仍 为"2225"。 ...

Financial Performance - Total revenue for the six months ended June 30, 2023, was SGD 11,982,837, a decrease of 18.6% compared to SGD 14,707,178 in the same period of 2022[5] - Gross profit for the same period was SGD 5,048,441, slightly up from SGD 5,028,537, indicating a stable gross margin[5] - The net profit after tax for the six months was SGD 584,393, down 56.1% from SGD 1,332,972 in the previous year[5] - Total comprehensive income for the period was SGD 383,275, a decline of 61.9% compared to SGD 1,007,138 in the prior year[5] - Basic and diluted earnings per share for the period were 0.08 cents, down from 0.11 cents in the previous year[5] - The company reported a pre-tax profit of SGD 590,165 for the six months ended June 30, 2023, a decrease of 63.9% compared to SGD 1,632,634 in the same period of 2022[10] - Confirmed revenue for the six months ended June 30, 2023, was SGD 11,982,837, a decrease of 18.5% compared to SGD 14,707,178 in 2022[18] - The group recorded a profit attributable to shareholders of approximately SGD 0.9 million in the first half of 2023, down from SGD 1.4 million in the same period of 2022[40] Assets and Liabilities - Current assets increased to SGD 39,340,316 as of June 30, 2023, compared to SGD 33,301,539 at the end of 2022, reflecting improved liquidity[6] - Total liabilities increased to SGD 20,250,653 from SGD 13,998,576, suggesting a rise in financial obligations[7] - The company's net asset value improved to SGD 25,442,652 as of June 30, 2023, compared to SGD 24,592,206 at the end of 2022[7] - Trade receivables rose significantly to SGD 8,623,294 from SGD 2,211,612, indicating a potential increase in sales or credit terms[6] - Trade payables increased to SGD 8,730,909 as of June 30, 2023, compared to SGD 476,557 at the end of 2022[29] - The group's total lease liabilities as of June 30, 2023, were approximately SGD 3.5 million, an increase from SGD 2.5 million as of December 31, 2022, due to lease renewals[52] - The asset-to-liability ratio as of June 30, 2023, was approximately 21.0%, up from 18.1% as of December 31, 2022[52] Cash Flow and Investments - Operating cash flow generated was negative SGD 1,110,615, compared to positive SGD 1,713,778 in the previous year, indicating a significant decline in operational efficiency[10] - The company incurred a net cash outflow from investing activities of SGD 120,891, a significant improvement from SGD 899,223 in the previous year[11] - Cash and cash equivalents at the end of the period stood at SGD 12,936,556, down from SGD 14,261,423 at the end of June 2022[11] - The group has approximately SGD 527,639 in undrawn bank financing available as of June 30, 2023[52] - The company maintains cash and cash equivalents at a level deemed sufficient by management to meet operational needs and reduce cash flow volatility[61] Revenue Breakdown - Revenue from labor dispatch and support services increased to SGD 7,540,287, up 11.2% from SGD 6,782,648 in 2022[16] - Revenue from dormitory services rose from approximately SGD 2.8 million to about SGD 3.6 million, primarily due to an increase in occupancy rates[36] - Revenue from minimally invasive surgical solution products decreased by approximately SGD 4.2 million, attributed to operations in China[36] - Other income for the six months ended June 30, 2023, totaled SGD 706,551, an increase of 54.4% from SGD 457,682 in 2022[20] - Other income increased from approximately SGD 0.46 million to about SGD 0.70 million, mainly due to procurement service fees recognized in Hong Kong[38] Expenses and Costs - The company paid interest of SGD 48,280, which is an increase from SGD 25,087 in the previous year, reflecting higher financing costs[11] - Administrative expenses rose from approximately SGD 4.0 million to about SGD 4.8 million, primarily due to the gradual recovery of the construction industry post-COVID-19[38] - The group incurred employee costs of approximately SGD 6.3 million in the first half of 2023, compared to SGD 4.8 million in the first half of 2022[57] Shareholder Information - As of June 30, 2023, the company has 632,500,000 shares outstanding, representing approximately 51.42% ownership by its major shareholder, Bao Lai International Limited[66] - The company did not declare or pay any dividends for the six months ended June 30, 2023, consistent with the previous year[25] - The company has not adopted any share option schemes during the reporting period[67] Future Plans and Developments - The board is considering expanding existing services to include value-added services such as skills training and workforce enhancement in the Asia-Pacific region, including China[36] - The group plans to explore various fundraising methods in capital markets in Hong Kong and/or other locations to support business development[36] Miscellaneous - The company has not disclosed the total transaction price allocated to unsatisfied performance obligations as they are part of contracts expected to be completed within one year[16] - The company primarily operates in Singapore, with nearly all revenue generated from this region, while some revenue from minimally invasive surgical solutions comes from China[17] - The group has not made any significant acquisitions or disposals of subsidiaries, associates, or joint ventures in the first half of 2023[56] - There were no significant events affecting the group from June 30, 2023, to the date of this interim report[69] - The audit committee has reviewed the unaudited interim results and found them to be prepared in accordance with applicable accounting standards and regulations[73]